Tag: PCSK9

ACC 2017: Positive final results from ORION-1 phase II study of...

The Medicines Company and Alnylam Pharmaceuticals have announced positive final results from the ORION-1 Phase II study of inclisiran, an investigational, first-in-class PCSK9 synthesis...

AHA 2016: Two thirds of patients experience plaque regression with the...

Amgen has announced that adding its PCSK9 inhibitor evolocumab (Repatha) to optimised statin therapy results in statistically significant regression of atherosclerosis in patients with...

Positive top-line results from phase 3 GLAGOV imaging study of evolocumab

The Phase 3 GLAGOV (Global assessment of plaque regression with a PCSK9 antibody as measured by intravascular iltrasound) trial has met both its primary...